Tangled alpha-synuclein proteins within a neuron

Unlocking Parkinson's: How Understanding Alpha-Synuclein Could Lead to a Cure

Beau Callahan in Health & Wellness August 2025 • 3 min read.

"A deep dive into the toxic protein at the heart of Parkinson's disease, and how targeting it could revolutionize treatment."

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions worldwide. Characterized by tremors, rigidity, and slow movement, PD significantly impacts the quality of life for those affected. While the exact cause remains elusive, a key player in PD pathology has emerged: alpha-synuclein.

Alpha-synuclein is a protein found in high concentrations in the brain, where it plays a crucial role in neuronal communication. However, in PD, this protein misfolds and aggregates, forming clumps known as Lewy bodies. These Lewy bodies disrupt normal brain function and are a hallmark of the disease.

Recent research has focused on understanding how alpha-synuclein becomes toxic and how we can prevent or reverse this process. This article explores the latest findings on alpha-synuclein's role in PD, examining its impact on cellular processes and the potential for novel therapeutic interventions.

Alpha-Synuclein: From Normal Function to Toxic Aggregation

Tangled alpha-synuclein proteins within a neuron

In its healthy state, alpha-synuclein is believed to aid in synaptic vesicle function, which is essential for neurotransmitter release. This process allows neurons to communicate effectively. However, several factors can cause alpha-synuclein to misfold and aggregate. These include:

Genetic Mutations: Specific mutations in the SNCA gene, which provides instructions for making alpha-synuclein, are linked to early-onset PD. These mutations can make the protein more prone to aggregation.
Oxidative Stress: An imbalance between the production of free radicals and the body's ability to neutralize them can damage proteins, including alpha-synuclein, promoting misfolding.
Impaired Protein Degradation: Cells have natural mechanisms for clearing out misfolded proteins, such as the ubiquitin-proteasome system and autophagy. When these systems fail, alpha-synuclein can accumulate and aggregate.

The aggregation of alpha-synuclein leads to a cascade of cellular dysfunction. These aggregates disrupt the normal function of mitochondria (the cell's powerhouses) and the endoplasmic reticulum (involved in protein synthesis and folding). They also interfere with intracellular trafficking, the process by which cells transport essential molecules.

The Future of Parkinson's Research: Targeting Alpha-Synuclein

While Parkinson's disease remains a complex challenge, the growing understanding of alpha-synuclein's role offers hope for new and effective therapies. By targeting the mechanisms that cause alpha-synuclein to misfold and aggregate, scientists aim to develop treatments that can slow down, halt, or even reverse the progression of this devastating disease.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is alpha-synuclein, and what role does it play in Parkinson's?

Alpha-synuclein is a protein that is highly concentrated in the brain. In its normal state, alpha-synuclein supports neuronal communication by aiding in synaptic vesicle function, which is essential for neurotransmitter release. However, in Parkinson's disease, alpha-synuclein misfolds and clumps together, forming what are known as Lewy bodies. These Lewy bodies disrupt normal brain function and are a hallmark of Parkinson's disease. Understanding the structure and function of alpha-synuclein is crucial to creating effective treatments.

What are Lewy bodies and how do they affect the brain in Parkinson's disease?

Lewy bodies are abnormal aggregations of misfolded alpha-synuclein protein that form inside nerve cells. The presence of Lewy bodies disrupts normal cellular processes. They interfere with intracellular trafficking, mitochondrial function, and the endoplasmic reticulum. By accumulating and disrupting these functions, Lewy bodies contribute significantly to the neurodegeneration observed in Parkinson's disease, causing motor and cognitive symptoms. Their formation marks a critical pathological event in the disease.

What causes alpha-synuclein to misfold and aggregate in Parkinson's?

Several factors can cause alpha-synuclein to misfold and aggregate. Genetic mutations in the SNCA gene, which is responsible for producing alpha-synuclein, can make the protein more prone to aggregation. Oxidative stress, caused by an imbalance between free radical production and the body's ability to neutralize them, can damage alpha-synuclein. Impaired protein degradation, where the cell's natural mechanisms such as the ubiquitin-proteasome system and autophagy fail to clear out misfolded proteins, can also lead to alpha-synuclein accumulation and aggregation.

How might targeting alpha-synuclein lead to new treatments for Parkinson's disease?

Targeting alpha-synuclein offers a promising avenue for new Parkinson's disease therapies. By understanding the mechanisms that cause alpha-synuclein to misfold and aggregate, scientists aim to develop treatments that can slow, halt, or even reverse the progression of Parkinson's. Strategies include preventing misfolding, enhancing protein degradation, and reducing oxidative stress. Because alpha-synuclein plays a central role in Parkinson's pathology, therapies aimed at modulating its behavior hold significant potential for disease modification.

What are mitochondria, the endoplasmic reticulum, and intracellular trafficking, and how does alpha-synuclein affect them?

Mitochondria are the powerhouses of cells, responsible for generating energy. The endoplasmic reticulum is involved in protein synthesis and folding. Intracellular trafficking is the process by which cells transport essential molecules. In Parkinson's disease, the aggregation of alpha-synuclein disrupts the normal function of all three, impairing energy production, protein processing, and molecular transport within cells. This disruption contributes to cellular dysfunction and neurodegeneration. By understanding how alpha-synuclein affects these critical systems, researchers aim to develop targeted therapies to protect these functions and slow disease progression.